NEW YORK, NY–(Marketwire – December 8, 2010) – Labs using DNA sequencers are more concerned with accuracy than cost in future purchases, according to a survey conducted by Kalorama Information. The healthcare market research publisher reported the survey findings in its recent report, “DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems).”

“A significant number of respondents chose accuracy over cost, ease-of-use or speed,” said Justin Saeks, Kalorama Information’s biotech analyst and author of the report. “This was true both for labs using first-gen or next-gen systems.”

The Kalorama Information survey of 120 laboratories using next-gen and capillary systems was carried out from July to September of 2010, with the majority in the latter portion. About 70% of the labs were academic; the remainders were hospital, government or independent labs. 70% of the hospitals were in North America, 12% in Europe and 18% in ROW. The bulk of respondents were core labs with more than a third doing contract work. Respondents were asked for the most important criteria in considering a new sequencer purchase. Accuracy rated highest for 78.8% of respondents. Cost per sample run was also important, rating second as a criterion with 63.6% of respondents. 

Kalorama Information found that the preference for accuracy occurred regardless of whether the survey respondent used a 454, SOLID, Illumina or Capillary System. Saeks, who has been analyzing sequencer markets for the past decade, was not surprised at the ranking of accuracy over other qualities in purchasing new sequencers.

“One of the things we heard from respondents was that accuracy is proportionately more important because in sequencing the margin of error is low,” said Saeks. “Even a .01% error rate adds up to a lot. And accuracy drives other areas — a clean sequence, for instance, will enable software algorithms to work well.”

Kalorama Information has been covering developments in the DNA sequencing markets since 2007. More information on this report, “DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems),” can be found at: http://www.kaloramainformation.com/redirect.asp?progid=80130&productid=2657156.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

Click here to see all recent news from this company

RICHARDSON, TX–(Marketwire – December 8, 2010) – KBM Group, the global leader in knowledge-based marketing solutions, has agreed to acquire Marketing Direct, Inc. (MDI), the leading provider of agency services to the healthcare industry. MDI is an integrated marketing services company with expertise in strategy, design and execution of marketing campaigns, from go-to-market strategies and sales-lead conversion to media placement, primarily for the healthcare industry. The acquisition strengthens and broadens KBM Group’s existing products and services for the healthcare market, augmenting the company’s core capabilities with a wide array of agency services such as creative and media placement, including digital media channels. Based in St. Louis, MO, MDI is a privately held company. Financial terms of the deal are not being disclosed, and the acquisition is subject to regulatory and shareholder approvals.

Founded in 1997, MDI has been ranked one of America’s fastest-growing private companies by Inc. Magazine in its annual Inc. 5000 survey for 2008, 2009 and 2010. The company’s growth has been driven by providing direct and interactive marketing services primarily to the healthcare industry, but the company has experience in retail and financial services as well. MDI’s capabilities span marketing services end-to-end, including: consulting services, developing and optimizing direct market channels, facilitating the sales process through sales force automation, determining the best mix of online and offline media, performing analytics and testing to ensure results, developing creative campaigns from messages to branding, optimizing websites and online strategies, and media placement and execution. Providing these multichannel marketing services to targeted industries has given MDI industry-specific expertise that has allowed it to help its clients acquire millions of customers and engage them to improve healthcare outcomes.

With the combined strength of the acquisition, KBM Group is also officially announcing the launch of KBM Group: Health Services, a new business practice focused on improving how companies across the healthcare continuum engage with consumers and healthcare professionals. KBM Group: Health Services will immediately intensify its focus on helping organizations within the healthcare ecosystem create more meaningful engagements with consumers for the ultimate goal of improving healthcare outcomes while reducing the overall cost of healthcare services. Dennis Barnes, Jr., President & CEO of MDI, will become President, KBM Group: Health Services. The new unit will remain part of Enterprise Services within KBM Group.

“While KBM Group and MDI have been recognized and established leaders within healthcare for several years now, current and impending changes to healthcare require a more holistic approach to multi-channel engagement if we are to substantially reduce costs while improving outcomes,” says Dennis Kooker, KBM Group’s President & COO for Enterprise Services. “Combining KBM Group’s industry standards for data, analytics, and database services delivered through its Consumer Healthcare Engagement Platform (CHEP) with MDI’s expertise in blending creative content and program design with analytics was an obvious combination. MDI has also invested heavily within innovative digital channels that mark the future of consumer engagement. The fundamental beliefs of our organizations and how to serve the healthcare ecosystem are very much aligned.”

Dennis Barnes, President & CEO of MDI, says, “We look forward to contributing our successful record of growth and healthcare expertise to KBM Group, and to integrating our capabilities with KBM Group’s superb data and analytics capability. As an agency specializing in healthcare, we are impressed with the level of healthcare subject matter expertise and the vision that KBM Group has created for the healthcare ecosystem. I am thrilled to have the opportunity to lead an organization with the combined resources and capabilities that KBM Group Health will possess; not to mention how exciting it is to be able to prove our more fundamental goal of driving down the cost of healthcare in this country without needing to make villains out of the healthcare providers.” 

New York-based mergers & acquisition firm AdMedia Partners acted as exclusive financial advisor to MDI in the transaction (www.admediapartners.com). For information about MDI and its transition to KBM Group: Health Services, go to www.marketingdirect.com.

About KBM Group
KBM Group is the global leader in knowledge-based marketing solutions. Expert in both digital and traditional direct marketing, KBM Group helps companies manage, analyze and optimize marketing data to engage more effectively with their customers and prospects. KBM Group’s integrated, world-class solutions include strategic consulting, digital services, database services, analytics, marketing management, response services, data and marketing outsourcing. The company has 16 offices in nine countries serving global, enterprise and B2B2C-focused companies. KBM Group’s parent company, Wunderman is part of Young & Rubicam Brands and a member of WPP (NASDAQ: WPPGY). www.kbmg.com.

Click here to see all recent news from this company

DENVER, CO–(Marketwire – December 8, 2010) – Like the scale in the doctor’s office, the numbers can be daunting. Similarly, the statistics that reveal an increasingly overweight America — 67 percent and rising — are sending shivers down the spine of this nation’s health care system, especially in corporate America where the costs of keeping employees healthy are threatening both the bottom line and the country’s economic future.

Today it costs employers an estimated $13,000 annually to provide premium health care benefits for a typical employee and his or her dependents, and that figure has gone up 10 percent each year for the past decade. Of that annual amount, almost $10,000 is paid by the employer. 

In an attempt to stem the tide, Denver-based incentaHEALTH has focused on one of the biggest drivers of health care costs: obesity. Overweight and obese employees incur over $1,500 in additional costs for the employer each year. In response, incentaHEALTH has developed a unique program that pays employees and their families to lose weight, stay healthy and remain productive. Blending technology, ingenuity, medical expertise, and employer resources, it is designed to encourage greater participation by employees in typical company health plans.

According to Todd McGuire, Chief Technology Officer, who co-founded the company in 2002 with CEO Jack Rule, the idea for incentaHEALTH was developed after discovering that among the most pressing issues facing the business world at the time were runaway health care costs and obesity.

“In 2002 we weren’t happy with the wellness programs used by the rest of the industry, so we created our own,” McGuire said. “Our technology authenticates health outcomes instead of relying on people to self-report. Since we are paying cash incentives, you don’t want somebody to send a friend down to weigh in for them.”

The centerpiece of the incentaHEALTH system is the patented HEALTHspot kiosk which, when strategically placed throughout a company’s facilities, provides:

• Automated biometric measurements of weight, blood pressure and body mass index (BMI) using authenticated measurements (not self-reported)
• Instant feedback to participants and program administrators
• 24-hour, low cost operation and remote maintenance
• Enhanced privacy
• Full-body digital imaging to keep track of participant progress and create a visual progress report
• Complete and accurate electronic records for both employee and employer

Supporting the kiosks, the program uses a variety of communication tools to reach all employees and motivate them to participate. Says McGuire, “Behavior change is a daily battle. It won’t occur with an occasional newsletter. A better approach is a daily coaching plan using emails and text messages that shows employees and their dependents exactly how to eat and exercise.” The program incorporates onsite kickoff sessions and printed support materials to reach employees without email access.

“The national view of health and wellness has matured significantly since we started our business,” said McGuire. “After extensive research of the problem and conducting surveys of the workforce, the wellness industry has found that people are inactive, overweight, have high blood pressure and are not eating properly. Employers are now demanding programs that result in real behavioral changes to tackle these issues.”

“Historically, employers have offered $50 to employees just to sign up for a wellness program, whether they used it or not,” he added. “What we do is shift from an incentive for participating to an incentive for measured performance. For example, if an employee signs up for our program and achieves a 15 percent weight loss, they will get paid, in actual dollars on a brightly colored check, when they weigh in at the HEALTHspot kiosk every 90 days.” The program pays incentives ranging from $15 to $150 per quarter to all employees based on the amount of weight they lose, so every level of success is rewarded.

So far, the incentaHEALTH approach to corporate wellness is working. Organizations across the globe are signing up — companies like Jackson National Life Insurance Co., Virginia Tech, Kaiser Permanente, Long Beach Memorial Medical Center, Accident Fund Insurance Company of America, U.S. Department of Health and Human Services, and others that are concerned about their employees’ health.

“incentaHEALTH has become an integral part of our overall wellness program, which helps our associates make healthier lifestyle choices,” said Cheng Hsu, benefits manager at Jackson National.

And users are noticing a big difference in their health.

“I’ve lost 70 pounds on this program. I am now eating healthy, watching my portion sizes and exercising,” said one employee participant. “It was a true godsend.”

About incentaHEALTH
incentaHEALTH is an innovative health care technology company based in Denver, Colorado. incentaHEALTH’s fully outsourced, employee weight management program is designed to help organizations reduce their health care costs by offering incentives to employees for improving their health. This is achieved by helping employees manage their weight through the use of interactive email coaching, workplace weigh-ins on private kiosks, and cash rewards for maintaining long term health improvements. For more information, visit www.incentahealth.com.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – December 8, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today announced it has completed a pilot clinical study to measure the feasibility of using its Onko-Sure® in vitro diagnostic (IVD) cancer test kit as a veterinary tumor marker initially for cancer detection in domestic cats.

Preliminary data from the Onko-Sure® assay pilot study measuring domestic cat serum suggests RPC’s Onko-Sure® IVD cancer test may potentially detect cancer in domestic cats. In this pilot study, RPC ran samples from confirmed normal domestic cats and domestic cats with cancer. For cats with cancer, RPC ran a serum sample obtained first when the cats were cancer-free and another sample subsequently when the cats were confirmed with cancer. The relative levels of Onko-Sure® for the cats were compared using the Onko-Sure assay and showed a 2,853% increase in Onko-Sure levels versus the healthy sample. RPC is currently engaged in full clinical trial including 71 samples, which includes an antigen characterization that involves testing to identify direct evidence that RPC’s Onko-Sure® IVD cancer test kits are effective in cancer detection in domestic felines.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “This development is anticipated to open the use of our Onko-Sure® assay as a veterinary cancer tool that could play an integral role in the screening and early detection of cancer for veterinary patients and further enhance RPC’s strong portfolio of novel oncology products. This is truly an exciting development for the Company and our valued shareholders.”

Onko?Sure is a simple, non?invasive, patent?pending and regulatory?approved IVD test for use as an aid in early detection of cancer. Onko?Sure enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko?Sure is approved by the US FDA for the monitoring of colorectal cancer, Health Canada as a lung cancer screen and cancer monitoring tool, and the European Union, Indian government, Korean government, and Taiwanese government as a cancer monitoring or cancer screening test. Onko?Sure test kits are currently sold as a blood test for cancer in Europe, India, Taiwan, Korea, and Vietnam and in Chili for research use.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – December 8, 2010) – Salesforce.com Dreamforce Conference — Appirio has selected RehabCare as Cloud Pioneer of the Year, an annual award given by Appirio to companies and individuals that demonstrate leadership in cloud computing initiatives and a commitment to moving their business forward using public cloud platforms. 

RehabCare is a leading provider of physical rehabilitation program management services in more than 1,260 hospitals, skilled nursing facilities and other long-term care facilities in the U.S. They own and operate 35 hospitals, employ more than 18,000 people and report $1.6B in revenue. RehabCare’s commitment to using cloud-based and mobile platforms to improve patient care while growing their business and staying ahead of complex healthcare regulations stood out among more than a dozen nominated organizations.

“We view our technology investments as core to our company’s future and critical for patient care, and we think it can be a model for others in this industry,” said Dick Escue, CIO of RehabCare. “Using cloud computing, we can do things now that we wouldn’t have even thought possible two years ago. We see it as a huge differentiator for our company and the care we can provide.”

Over the past year, RehabCare has invested in building out an integrated technology platform that has dramatically improved their patient intake and referral process, the way they track, benchmark and improve rehabilitation procedures, and the way they report and communicate progress to Medicare, patients and their families. RehabCare has standardized on platforms, such as Salesforce, Force.com, Google Apps, and Google Health, and are in the process of developing a comprehensive cloud-based Electronic Medical Record platform that will begin rolling out next year. They’ve armed thousands of therapists with iPhones and iTouches and have been highlighted by Apple for their use of the iPad in healthcare.

Appirio’s Cloud Pioneer awards program was introduced earlier this year to recognize the champions and change agents among Appirio’s customers — those who recognize the unparalleled benefits of public cloud platforms and drive projects that are not only successful but truly impactful for their organization. Each Cloud Pioneer award winner is chosen by Appirio’s leadership team, based on nominations from the company’s delivery managers and cloud architects. Other 2010 Cloud Pioneer award winners include individuals at AIG Edison, Dolby Laboratories, DeVry University, Dunkin Brands, Japan Post Network and Perceptive Software. 

“The recipients of Appirio’s Cloud Pioneer award illustrate the potential of cloud computing to shape business strategy, accelerate innovation and drive competitive advantage,” said Chris Barbin, CEO of Appirio. “The executives and IT team at RehabCare who are applying cloud and mobile technologies throughout their business exemplify every one of these benefits. We are privileged to work with them and all of our Cloud Pioneers.”

Appirio’s 2010 Cloud Pioneers
Dick Escue and Jayson Chitwood (RehabCare), Tohru Futami (AIG Edison Life), Mary Ann Lusk and John Cunningham (DeVry University), Curtis Hodge and Scott Sullivan (Dolby Laboratories), Michael Wordell, Erik Astin, Greg O’Connor and Jon Cohen (Dunkin Brands), Neale Wooten (Perceptive Software), Yoshihiko Ohta (Japan Post Network)

About Appirio
Appirio (www.appirio.com) is a cloud solution provider offering products and professional services that help enterprises accelerate their adoption of cloud applications and platforms. Appirio’s innovation and expertise has been recognized by BusinessWeek as one of America’s Most Promising Startups and by AlwaysOn as 2010 On-Demand Company of the Year. Appirio has helped more than 180 leading enterprises implement, build and manage mission critical cloud solutions using salesforce.com, Google, Workday and Amazon. We are proud to serve a wide range of customers such as Avago, the City of Los Angeles, Diversey, Dunkin Brands, Flextronics, Japan Post Network, Ltd., IMS Health, Motorola, Qualcomm, RehabCare, Safety Kleen, Starbucks and VMware, as well as the 5,000 companies that use Appirio’s products to connect and extend cloud platforms. Founded in 2006, Appirio has offices in the U.S. and Japan, and is backed by Sequoia Capital and GGV Capital.

PRINCETON, NJ–(Marketwire – December 7, 2010) – More employers and insurance companies are providing domestic medical travel incentives such as waived deductibles; coinsurance plans and covered travel expenses if employees will simply travel within the United States for healthcare travel or to another region or city for medical care. “The savings are significant and therefore insurers and third party administrators are partnering with healthcare providers for new revenue sources, especially in these times of reduced revenues thanks to healthcare reform,” said David Goldstein, president of Health Options Worldwide (HOW), an online medical tourism agency that provides high-quality low-cost healthcare options domestically and internationally.

In fact, large employers are negotiating with American hospitals located in other states and encouraging employees to seek healthcare for major illnesses and surgeries in other regions of the country. “Employers are partnering with insurance companies and hospitals to save money on their employee health plans,” said Goldstein. “They are accomplishing this by negotiating single rate packages with high-quality hospitals in other states, to include all fees for medical services in a single treatment program.”

Employers who adopt “domestic medical travel” can reduce healthcare costs 20-40% simply by referring employees to American facilities with higher-quality care and lower negotiated prices than in their own hometown. Health industry analysts believe that medical tourism, and more specifically domestic medical travel, could improve overall quality of care and help drive down costs with national competition.

Healthcare savings in domestic medical travel programs are realized from lower prices, which are negotiated between the company and the out-of-state hospital. Reduced complications from procedures performed at these high-quality hospitals also help the bottom line. Follow-up care is handled at the local hospital and covered as part of the treatment program, under the company’s insurance plan.

“Domestic medical travel is not a new concept as employers and insurers have always referred patients to high-quality facilities elsewhere for complex procedures,” said Goldstein. As healthcare costs continue to rise nationwide, domestic medical travel is a way for major employees to control escalating costs and provide their employees with the best quality care.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – December 7, 2010) – Jane Green, PhD, president of Morley Research Consortium, and Donald Johnson, Chief Operations Officer of Opus Institutional Review Board, have been appointed to the India-US Business Network (IUSBN) Board of Directors.

In this capacity Dr. Green and Mr. Johnson will be integral to shaping the relationship between India and the United States as the two countries explore and develop mutually beneficial opportunities. The initial four areas of interest for the IUSBN are Biotech, Pharma, Diagnostic, Devices and Health Care; Cold Chain; Education; and Renewable Energy. 

The two Atlanta leaders, who both have extensive experience in clinical research, have been asked to sit on the Biotech Committee for the IUSBN. This committee is focused on matching companies from each country with counterparts in research and development.

“This is both an honor and an opportunity,” said Dr. Green. “By furthering cooperation with India, we achieve the ability to improve the level of research and development in the area of biotech in both countries. I believe this exchange of ideas and information can create exponential advances in developing products and technologies that will benefit the entire world.”

Dr. Green’s organization, the Morley Research Consortium, assists device and drug companies to achieve their research goals of bringing a new product to market through its contract research organization which additionally provides research compliance, total trial management, contracting, site identification and training.

“India is a world leader in technology innovations, and expects to achieve similar success in the biotech field,” said Mr. Johnson. “I am pleased to be able to play a role in helping reach that goal, while also strengthening and benefiting U.S. companies.”

Mr. Johnson manages Opus Institutional Review Board (IRB), the ethical overview organization mandated to review clinical research studies worldwide. Opus IRB has a board of directors consisting of the country’s top practicing physicians in a variety of clinical specialties and encompasses over 20 medical disciplines.

Mr. Johnson and Dr. Green are the first two board members of the IUSBN from the southern region of the U.S. and they are planning the initial Atlanta area meeting of the IUSBN in the first quarter 2011 for others interested in the organization.

Learn more about IUSBN at www.iusbn.org. 

IRVINE, CA–(Marketwire – December 7, 2010) – SK&A, A Cegedim Company, a leading provider of healthcare information solutions and research, today announced the launch of its new web video series, “My Data Dilemma.” The series will feature SK&A clients from industries such as pharmaceutical, biotechnology, healthcare consulting, medical device and others, discussing their specific marketing challenges and how they overcame them through effective targeting and use of SK&A’s healthcare data products.

Episode one of “My Data Dilemma” takes viewers inside a healthcare consulting company that was challenged with identifying and reaching all U.S. blood bank directors and maternity nurses to execute surveys in support of two campaigns. One of the company’s senior vice presidents identifies the challenge the organization faced, the strategy that was executed with SK&A’s help and the results the company received from the project.

“Video is a great medium to effectively deliver the value and insight of successful marketing strategies and tactics to our large base of clients and prospects, and I am excited the SK&A marketing department has provided an insightful and engaging series that will help our customers learn from one another,” said SK&A’s Dave Escalante, Vice President of Data and Information Solutions. “With healthcare marketing strategies changing so rapidly, we feel it is important to embrace our leadership position in this space, connect our community of users, and promote the exchange of ideas.”

SK&A’s commitment to creating a community within the healthcare marketing industry is reflected in its social media outreach efforts, which span across its blog, LinkedIn, Facebook, Twitter and YouTube. Users can find news articles, discussions and other resources available at SK&A. All of SK&A’s market insight reports, press releases and company announcements can be accessed through these social media channels. The web video series will be posted on SK&A’s website and YouTube, with access from all the social media web pages.

Coming soon in episode two, “My Data Dilemma” cameras visit the office of a global biotech company that was challenged with identifying all the U.S. hospitals that treat a specific disease. Tune in to see how they found a solution for their marketing research challenge.

To view episode one of “My Data Dilemma,” visit http://www.skainfo.com/video_series.php. 

About SK&A, A Cegedim Company:
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 800,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering.  

About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com 

Click here to see all recent news from this company

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – miCARD and Gold Wing Road Riders Association, the world’s largest social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles have partnered to provide GWRRA with a co-branded, medical information card that prepares association member/riders for an unanticipated medical emergency.

“One of the highest priorities at GWRRA is to ensure the health and safety of our 74,000+ members,” said Ed Price, Marketing Director at GWRRA. “We are pleased to join forces with miCARD to ensure our association riders are prepared for any kind of a medical event. No matter where our members go, we know that the lifesaving medical information on miCARD will be with them. I personally carry miCARD in my wallet all the time, as I travel extensively.”

Motorcycle Fatalities on the Rise
The National Highway Transportation Safety Administration projects more than 100,000 motorcycle injuries will occur this year alone. Even with the advent of statewide motorcycle safety campaigns to help automobile drivers become more aware of motorcyclists, fatalities continue to rise. Carrying medical information ensures that emergency personnel have the critical information they need to make lifesaving decisions should an accident occur.

miCARD is the only medical information card and online Personal Health Record(PHR) designed by an emergency physician. In less than one minute, miCARD gives medical personnel in the field a readable summary of a member’s vital medical information. This includes: current medical conditions, critical medications, emergency contacts, allergies and more. miCARD’s wallet card is further supported by an online PHR which stores additional member information such as: advance directives, physician contacts, EKG’s, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

“Critical decisions about your health are made in the first few minutes of your emergency care,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “If you are unconscious or incapacitated, medical personnel have no knowledge of your existing medical conditions, critical medications or other important details which could impact your care and save your life.”

miCARD is a low cost solution to the problem of emergency preparedness and care and can be created securely online in minutes. To ensure the health and safety of your association members or to enquire about co-branding opportunities with miCARD please visit www.micard.com/partners or contact us directly at (866)596.2956.

About miCARD
Headquartered in Scottsdale, AZ, miCARD is a physician designed, medical information card and online personal health record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information, 24/7 worldwide. miCARD is registered with the USPTO under patent & trademark protection. For more information about miCARD please visit www.micard.com or contact us at (866)596.2956.

About Gold Wing Road Riders Association
 Founded in 1977, The Gold Wing Road Riders Association (GWRRA) is the world’s largest single-marque social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles. Dedicated to our motto, Friends for Fun, Safety and Knowledge, GWRRA members enjoy the freedom of belonging to a not-for-profit, non-religious and non-political organization with more than 800 active chapters, serving nearly 80,000 U.S., Canadian and international members in 53 foreign countries.

PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG’s Pharma & Biotech Licensing & Partnering — scheduled for March 3-4, 2011 at the Doubletree Hotel San Diego Downtown in San Diego, CA — is designed to bring together EVPs, SVPs, Chief Business Officers, COOs and other Senior Management from Pharmaceutical and Biotech companies involved in licensing, business development and strategic alliances and partnerships. This educational and networking forum will provide insight and guidance to pharmaceutical licensing, business development and deal making executives from across the world — covering issues that will help pharmaceutical companies both large and small to structure the best deals, carefully monitor risks and, perhaps, find their next partner. Executives from across the country will gather together to exchange ideas and information. 

Key issues to be addressed include:

• What are the best practice strategies in developing an effective win-win licensing deal?
• Early versus Late Stage Partnering Opportunities
• Role of Corporate Investors in Today’s Deals
• The Evolving Business Model of Building a Biotech
• What Uncertain Financial Markets Mean for Deal-Making
• Maximizing Your Company Value Through Non-Traditional Alliances

Hear from representatives of large, medium, and small pharmaceutical as well as biotechnology companies as they share their insights on the evolving state of the industry. Some key faculty speakers include:

• Michael Shih, Senior Director, Business Development, Eisai Inc.

• Dr. Robert Baughman, PharmD PhD, Vice President Experimental Pharmacology, MannKind Corporation

• Linda A. Egger, PhD, CLP™, Senior Director, Scientific Liaison External Scientific Affairs – Diabetes and Obesity Licensing, Merck & Co.

• Dr. Sameeh M. Salama, Senior Director, Business Development, NAEJA Pharmaceutical Inc.

• Christoph Pittius, Ph. D., Executive Director, Business Development & Licensing, Novartis Oncology

• Daisy Rivera-Muzzio, Senior Director EP Product Licensing, Portfolio Development, Pfizer

• Allen Downs, Senior Executive Director, Licensing & Business Development, Purdue Pharma

• Michael D. Step, Senior VP, Corporate Development, Santarus, Inc.

• Gwen Melincoff, Senior Vice President of Business Development, Shire Pharmaceuticals

For complete information about this event visit: http://www.iibig.com/P1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. For more information, visit: http://www.iibig.com. 

PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG returns to America’s Healthcare Silicon Valley to present the industry-leading Investment and M&A Opportunities in Healthcare, January 25-26, 2011, at the Nashville Convention Center in Nashville, Tennessee. In 2011, experts are predicting an increase in middle-market M&A deal flow in all sectors — however, healthcare will continue to lead all others. Now that financing is becoming easier to find, pent up demand for deals in the middle-markets, and especially in this sector, are expected to increase dramatically. At this conference, attendees will hear from and network with experts and insiders on the status of deal-making in the healthcare sector and how and where deals are getting done.

Executive Speaking Faculty Includes: Alvarez & Marsal; Bass, Berry & Sims PLC; Belmont Village Senior Living; Benesch, Friedlander, Coplan & Aronoff LLP; Bertram Capital Management LLC; Capella Health; Coker Capital Advisors; CredenceHealth; Cressey & Company LP; Diatherix Laboratories, Inc.; DOHI; Epsilon Securities, LLC; EpsteinBeckerGreen; GTCR Golder Rauner, LLC; Healthcare Finance Group, LLC; Healthcare Productivity Automation; IASIS Healthcare Corporation; Iora Health; MedSolutions; Nashville Health Care Council (NHCC); Oak Hill Capital Partners; Penn Medicine; PricewaterhouseCoopers; Raymond James & Associates; Regence Group (Blue Cross/Blue Shield Oregon and Utah); RehabCare Group, Inc.; Renal Advantage, Inc.; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; SunTrust Robinson Humphrey; Tenet Healthcare; and Vanguard Health Systems.

Conference Sponsors include: Bass, Berry & Sims PLC; EpsteinBeckerGreen (EBG); PricewaterhouseCoopers; SunTrust Robinson Humphrey; Alvarez & Marsal; Benesch; Healthcare Finance Group (HFG); Raymond James & Associates, Inc.; Coker Capital Advisors; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; and Whyte Hirschboeck Dudek S.C.

Register by December 31, 2010 and Save $200! Healthcare Providers: Register at $595
For more conference information and/or to register: http://www.iibig.com/F1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. We provide learning and networking settings for some of the business community’s BIGgest thinkers — those who occupy the highest levels in their companies and organizations. Our events focus on the most pressing and timely issues facing decision-makers in today’s global economy. For more information, visit: http://www.iibig.com. 

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced the successful completion of a Phase 3 contraceptive trial of the company’s contraceptive gel product candidate named Savvy® (C31G). The study met its primary endpoint and was conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), in the Contraceptive Clinical Trials Network at 14 sites in the United States. The results of the NICHD study are published in Obstetrics and Gynecology, v.116, pages 1265-1273, in December, 2010.

The Phase 3 trial was a randomized, double-masked, controlled comparator study to assess whether a gel containing the spermicide, C31G, was non-inferior to Conceptrol®, a commercially available product containing nonoxynol-9 (N-9). The clinical investigators found that C31G was not inferior in contraceptive efficacy to the comparator drug Conceptrol®. Thus, the study met its primary objective. Moreover, the gel was well-tolerated and had a high degree of acceptability in women who completed the study. No drug-related serious adverse events were observed with C31G. Drug-related side effects of C31G were generally mild and did not lead to discontinuation.

Currently, all spermicides commercially available in the U.S. contain the active ingredient N-9 in a carrier such as a gel, film, cream, foam, suppository, or tablet. N-9 has been reported in some studies to cause irritant and allergic reactions in some users. Although the Conceptrol® product was effective and well-tolerated in the NICHD comparative trial, there were a significantly lower number of drug-related events with the C31G gel and fewer women discontinued the study due to drug-related side effects. In an interview with Reuters Health, lead researcher Dr. Anne E. Burke of The John’s Hopkins School of Medicine stated, “There are concerns with nonoxynol-9, such as vaginal side effects and genital irritation for some users. It seems that C31G might offer improvements in those regards.” C31G does not contain nonoxynol-9 and, if commercialized, may offer a welcome alternative for women who seek a non-hormonal method of contraception. 

C31G previously was the subject of two Phase 3 clinical trials conducted in Africa, supported by Family Health International and the United States Agency for International Development, to determine whether C31G was safe and effective for reducing women’s risk of acquiring HIV infection. The external independent Data Monitoring Committee reviewing those trials concluded in 2005 and 2006 that, while there were no safety concerns based on the results of the studies to date, continuing the trials would not allow the effect of C31G on HIV acquisition to be determined because of a lower than expected rate of HIV seroconversion in the trials. The committee determined that continuation of the trials was not warranted due to a lack of statistical significance between C31G gel and the vehicle control in the interim data. Accordingly, the trials were discontinued.

Adamis estimates that the market for a product with the characteristics of C31G to be in the $500 million range. Dr. Dennis J. Carlo, President and CEO, stated, that “Since the product does not fit in the core business of the company, Adamis is currently evaluating various out-licensing opportunities. We are currently in discussions with multiple organizations that have a focus or business unit in the area of contraception.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals has three wholly-owned subsidiaries: Cellegy Holdings, Inc.; Adamis Corporation; and Biosyn, Inc. Adamis Corporation has two wholly-owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Adamis Viral Therapies is focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company’s ability to successfully develop and market C31G assuming it is approved for marketing by the FDA and other regulatory authorities; regulatory issues or delays with the FDA; and the intellectual property protection that may be afforded by any patents or patent applications relating to C31G. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. These risks and uncertainties include, but are not limited to: whether C31G will be approved for marketing by the FDA and other regulatory authorities; whether the company will be able to obtain required funding to pursue activities relating to C31G; whether C31G is a commercially viable product and can be commercialized, manufactured, and marketed in a cost-effective manner; the extent of consumer demand for any such product; and whether any third party will be interested in entering into agreements relating to development and marketing of C31G. It is uncertain whether C31G will ever be commercialized or whether the company will ever realize revenues therefrom. Certain of these risks, uncertainties, and other factors, as well as other risks and uncertainties relating to the company’s business are described in greater detail in Adamis’ filings from time to time with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

NEW YORK, NY and JERUSALEM–(Marketwire – December 7, 2010) – The International Center for Autism Research and Education (ICare4autism), a New York-based charity, announced plans to create the world’s first Global Autism Center on Mt. Scopus in Israel, dedicated to catalyzing breakthrough innovation in autism research and treatment. In a ceremony at Jerusalem‘s City Hall hosted by Mayor Nir Barkat, ICare4autism’s President Joshua Weinstein signed an agreement paving the way for ICare4autism to acquire the campus of Bezalel Academy of Art in 2013, and convert it into a center, housing:

• State-of-the-art autism research facilities to serve as a platform for global collaboration.

• The world’s first university-level school of autism studies, to raise therapeutic standards worldwide.

• A model school, applying the latest research, technology and design to the needs of students across the Autistic Spectrum.

• A foundation to support transformative global collaborations in autism education and treatment.

Joshua Weinstein said, “To tackle the global autism epidemic, we need a community of researchers, educators and advocates that reaches across borders. Our new Center will give us the ability to convene and empower that community.”

Said Dr. Eric Hollander, Chairman of ICare4autism’s Scientific Advisory Council, “The Center will drive the research needed to discover the etiology of autism, ultimately leading to better methods of detection and treatment.”

Said Mayor Barkat, “We welcome ICare4autism’s plan to create a Global Autism Center on Mt. Scopus, and we look forward to the breakthroughs in research that will emanate from its campus to benefit the entire world.”

About Joshua Weinstein, MBA and MA Ed
Mr. Weinstein is the Founder of ICare4autism, which encompasses Shema Kolainu – Hear our Voices School and Center for Children with Autism in New York City, and Tishma – ABA School and Center for Children with Autism in Jerusalem, Israel.

About Dr. Eric Hollander, MD
Dr. Hollander, Chairman of the Advisory Council of ICare4autism, is a renowned psychiatrist on the faculty of Montefiore Medical Center University Hospital of Albert Einstein College of Medicine, former Chair of Psychiatry at the Mt. Sinai School of Medicine and Director of the Seaver and Greater New York Autism Center of Excellence.

id=”nav_links”>

TUSTIN, CA–(Marketwire – December 7, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) in partnership with Jaiva Technologies, today announced the formation of NuVax Therapeutics, Inc. (“NuVax”) — a wholly owned subsidiary of Radient Pharmaceuticals. The formation of NuVax Therapeutics is a strategic move on the part of RPC to enhance the Company’s Q2 2010 collaboration agreement with U.S.-based Jaiva Technologies — a biotechnology company focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products. 

NuVax, a clinical stage pharmaceutical company, aims to develop novel immune-gene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Through the newly formed NuVax Therapeutics, RPC and Jaiva Technologies will utilize RPC’s Combined Immunogene Therapy (“CIT”) cancer therapy to carry out human phase II clinical trials and develop products that will be first in-line therapies for largely unmet medical needs for cancer. The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialization, including the development and in-licensing of the up to five additional cancer-fighting technologies will be managed through NuVax under the leadership of Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia. Dr. Bhatia’s team will be responsible for engagement with clinical laboratories, hospitals and physicians in multiple international locations; conducting clinical trials for CIT technology; securing government approval for the use of CIT as a cancer therapy and vaccine throughout select markets; expansion and management of stage II clinical trials in multiple international locations including the U.S.; and full commercialization of CIT and all other in-licensed therapies in other select international markets. 

In 2001, RPC acquired CIT for approximately US$2 million in cash. The Company has since invested approximately US$1 million in additional capital for patent protection with a U.S. patent issued May 25, 2004. Developed by Dr. Lung-Ji Chang, CIT is a cancer therapy that works by simultaneously incorporating two genes directly into a patient’s tumor cells to enhance their immune system’s natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang currently serves as a consultant to RPC for the continued development of CIT and other gene therapies.

According to RPC Chairman and CEO Mr. Douglas MacLellan, “The formation of NuVax Therapeutics provides a unique platform to significantly accelerate and expand our planned collaboration with Jaiva Technologies, specifically as it relates to the commercialization of CIT, in-licensing new cancer therapies and conducting stage II human clinical trials to ultimately introduce these products to market. Simultaneously, it allows us to dedicate RPC resources to the continued worldwide commercialization of our Onko-Sure In Vitro Diagnostic cancer test. Together we anticipate success through both Companies to drive long-term growth and shareholder value.”

To support the growth and success of NuVax, RPC and Jaiva Technologies have established an internationally renowned executive and scientific team and board of directors that include RPC Chairman and CEO Mr. Douglas Maclellan, RPC COO and Chief Financial Officer Mr. Akio Ariura, Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia, RPC Board member Mr. Michael Boswell, Dr. Lung-Ji Chang, Professor of Molecular Genetics and Microbiology at the University of Florida Gainesville, and Dr. Afsaneh Motamed-Khorasani, Director of Oncology at RPC.

New to the team is Dr. Donald P. Francis — Dr. Francis worked for CDC from 1971 to 1992: smallpox (assigned to WHO) in India, Bangladesh, Sudan and the former Yugoslavia, cholera in Nigeria, Ebola in Sudan, Assistant Director, Hepatitis Division, Assistant Director, Virology Division. From 1981 he worked on HIV/AIDS: Coordinator of Laboratory Activities (Atlanta), Consultant to State of California (Berkeley) and San Francisco Mayor’s office. His AIDS efforts were chronicled in And the Band Played On, by Randy Shilts. In 1993 he joined Genentech where his HIV vaccine work began. In 1995, Dr. Francis co-founded a spin-off of Genentech called VaxGen where the world’s first efficacy trials were completed in the United States, Canada, Holland and Thailand. In 2004, Dr. Francis retired from VaxGen to establish a not-for-profit foundation, Global Solutions for Infectious Diseases, dedicated to developing vaccines for the less developed parts of the world. In 2009, the first successful HIV vaccine trial was reported. That trial used GSID’s vaccine combined in a “prime-boost format” with one from Sanofi. In addition to HIV, Dr. Francis works with international vaccine manufacturers on vaccines for dengue and influenza. He is a frequent consultant for WHO. Dr. Francis is anticipated to serve as an advisor and member of NuVax’s Board of Directors of NuVax.

After completing undergraduate studies at the University of California at Berkeley, Dr. Francis received his M.D. from Northwestern University and his Doctor of Science in Virology from Harvard. In addition, he completed his pediatric training at the University of Southern California Medical Center in Los Angeles and his infectious disease training at Harvard.

About Jaiva Technologies
Jaiva Technologies is a US?based biotechnology company founded by Dr. Umesh Bhatia that is focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products, including RPC’s CIT cancer therapy and vaccine.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – December 7, 2010) – The Southeastern Medical Device Association’s (SEMDA) 5^th annual conference will take place on March 29-30, 2011, adding a half day to the popular medical device event. Recognized as the premier gathering for the Southeast medical device industry, the conference balances presentations by medical device companies to investors with educational programs and networking opportunities.

Specifically designed to meet the needs of medical device industry professionals, the expanded format will allow additional time for educational and panel presentations, as well as one-on-one meetings.

Another addition for 2011 is a Gala Dinner, which will be held on March 29 at the Georgia Tech Hotel and Conference Center. The annual SpotLight Awards, which recognize individuals and companies that have made substantial contributions to the growth of the Southeastern medical device industry, will be presented during the dinner.

This year’s conference will be held at the Georgia Tech Global Learning Center, a midtown Atlanta conference facility that offers more room for presentations and meetings, complemented by state-of-the-art technology capabilities.

Other highlights will include:

• Keynote presentations from industry leaders
• Presentations from some of the region’s top existing and emerging medical device companies
• Workshops on a variety of topics including critical business issues affecting those within the industry
• Panel discussions by VCs and business development professionals, as well as a CEO Roundtable
• Numerous industry networking opportunities

For more information about the conference, sponsorship opportunities, presenting company application or registration, visit www.semdaconference.com.

About SEMDA
The Southeastern Medical Device Association (SEMDA) is a non-profit association that supports and promotes the medical device companies in the Southeast. Created in 2004, the association provides a unique resource and networking opportunity for medical device companies, entrepreneurs, inventors, physicians, and investors interested in accelerating the growth of the medical device industry in the Southeast. For more information, visit www.semda.net

Click here to see all recent news from this company

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – Stat Health Services Inc. and Scottsdale Healthcare announced today that they are offering Stat Health’s innovative STAT DOCTORS™ eHealth service as a supplemental health and wellness benefit for Scottsdale Healthcare’s employees and their covered dependents. 

Scottsdale Healthcare is the city of Scottsdale’s largest employer, operating three hospitals, a cancer center and several ambulatory care facilities with approximately 10,000 covered lives included in its employee medical plan. The agreement is Stat Health Services’ first contract with a major employer.

Like a virtual house call, STAT DOCTORS offers online on-demand care from a physician for many non-emergency minor illnesses or conditions. Effective today, Scottsdale Healthcare is launching the new employee benefit, just in time for the cold and flu season.

“With STAT DOCTORS our health plan participants will have the convenience of online access to board certified emergency physicians for care of common minor medical conditions, any time of the day or night. We believe this will be a popular benefit that our employees will take advantage of when they need care,” says Carol Henderson, senior vice president/chief talent officer for Scottsdale Healthcare.

55 percent of the 114 million visits to an emergency room are for non-emergencies¹. STAT DOCTORS leverages the Internet, advanced and proprietary technologies — including secure single sign-on, electronic health records (EHRs), ePrescribing and video conferencing — to bring patients a modern day virtual house call for treating minor medical emergencies.

By offering STAT DOCTORS, employers may benefit from increased employee satisfaction and retention, reduced employee absenteeism and decreased costs. Hospital employers such as Scottsdale Healthcare are also expected to benefit from their employees utilizing the STAT DOCTORS eHealth service for urgent care needs instead of hospital emergency rooms.

“In the past, patients had no choice but to either delay treatment or waste precious time and money waiting in emergency rooms or urgent care centers, exposed to seasonal viruses,” explains Alan C. Roga, M.D., Chairman and CEO of Stat Health. “Our STAT DOCTORS service solves this problem by using advanced technologies to provide convenient access to quality health care, 24 hours a day, 7 days a week.”

¹ “Addressing the Problem of Low Acuity Non-Emergent ER Visits,” Mercer Human Resources Consulting, January 2006.

About Scottsdale Healthcare
Scottsdale Healthcare is the community-based, nonprofit parent organization of the Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. A leader in medical innovation, talent and technology, Scottsdale Healthcare was founded in 1962 and is based in Scottsdale, Arizona. For more information, visit www.shc.org.

About Stat Health Services Inc.
Stat Health Services Inc. is an eHealth services company. Its STAT DOCTORS™ service provides members convenient and affordable online access to emergency medicine physicians for the diagnosis and treatment of urgent common minor medical conditions. STAT DOCTORS™ brings patients a modern day virtual house call. By providing such features as a secure single sign-on, a virtual waiting room, online medical consultations (eVisits), electronic health records (EHRs), and electronic prescribing (ePrescribing), STAT DOCTORS™ delivers a personalized, secure and superior health care experience. Stat Health’s network of emergency medicine physicians includes top board certified physicians who share a passion for delivering high quality health care, efficiently and effectively, by using the Internet and advanced technologies to treat today’s connected patients. Stat Health is headquartered in Scottsdale, Arizona. For more information, visit www.STATDOCTORS.com.

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty (P&C) claims and Collision Repair industries, today announced the successful close of its purchase of Ingenix’s P&C medical bill review (MBR) business. The purchase places Mitchell Workers’ Compensation Solutions (WCS) business and its SmartAdvisor™ medical bill review platform in a market leadership position, enabling the company to deliver to the insurance and managed care related industries advanced technology solutions with a proven track record of streamlining medical claims operations and improving cost containment.

“Since the intent to purchase the Ingenix MBR business was announced this October 20, Mitchell has experienced broad market acceptance and customer buy-in, the result of a carefully planned business and technology transition strategy that is being deployed within the context of Mitchell’s stable position and long-term experience in the P&C marketplace,” said Nina Smith-Garmon, senior vice president and general manager of the Mitchell Workers’ Compensation Solutions Division.

Smith-Garmon added, “The positive feedback we have received at the recent National Workers’ Compensation and Disability Conference® & Expo indicates that Ingenix P&C MBR customers anticipate a smooth, successful transition to Mitchell and the SmartAdvisor medical bill review technology platform. We will continue to enhance our solution for all our customers by adding to our already-extensive Preferred Provider Organization (PPO) networks and compliance expertise via strategic partnerships and acquisitions.”

Mitchell SmartAdvisor is a comprehensive bill review solution for workers’ compensation that leads the industry in its unique combination of performance software, client services, and best-in-class partnerships. Available through licensed or software-as-a service model, SmartAdvisor’s unique capabilities include customizable workflow modeling, Capstone® business decision rules engine, data analytics and reporting tools, Claims Examiner Portal for fast, secured, real-time access to bill data, and a proven technology platform that delivers on average 50-70% straight-through processing for improved efficiencies and lower costs. Visit www.mitchell.com/smartadvisor for more information or contact Mitchell Workers’ Compensation Solutions directly at 1-800-421-6705 to schedule a demo of the SmartAdvisor bill review system.

About Mitchell International, Inc.
Mitchell International (www.mitchell.com) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction.

About Mitchell Workers’ Compensation Solutions Division
Mitchell Workers’ Compensation Solutions (WCS), a division of Mitchell International, is a leading provider of workers’ compensation cost containment technologies and services. Insurance payers and other clients rely on Mitchell WCS’s best-of-breed medical bill review platform, the SmartAdvisor Software Suite, to improve their medical cost savings results. For more information, please visit www.mitchell.com/smartadvisor.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Dr. Vladimir Bogin as President and Chairman of the Board, Dr. Sergey Sablin as Vice President and Board Member, and Vladimir Zaharchook as Vice Chairman of the Board and Board Member. These changes were brought about as the result of a stock purchase agreement changing majority ownership of the company. 

“Dr. Sablin, who has a track record of excellence in drug discovery and development, is a founder of Selena Pharmaceuticals and a co-founder of Medivation, companies that advanced Dimebon, a Phase III technology that resulted in a deal with Pfizer with an over $200 million in the upfront payment. Dr. Bogin, a licensed physician with training from Brown and Yale, founded the contract research organization (CRO) Cromos Pharma, and has held Director-level positions with Big Pharma. Mr. Zaharchook is a successful businessperson and strategist. I am happy to entrust the future of our company in the hands of these experienced professionals,” said Dr. Neil Riordan, founder and former President and Chairman of Medistem, who resigned along with board member Dr. Roger Nocera as part of the acquisition. Dr. Riordan remains a shareholder and collaborator of Medistem. 

Medistem was founded in 2005 by Dr. Riordan as a developer, licensor, and licensee of adult stem cell therapeutics. To date technologies developed by Medistem have been used in more than 900 patients internationally. Currently Medistem, together with the Indiana company General Biotechnology, is nearing completion of additional experiments requested by FDA to allow for clinical trial initiation as part of its filed IND BB-13898 covering the use of Medistem’s “Endometrial Regenerative Cell” (ERC) product in patients at risk of amputation. 

ERC are a novel stem cell population isolated from menstrual blood that the company has demonstrated is capable of generating heart, brain, lung, liver, pancreatic, bone, muscle, blood vessel and cartilage tissue. Advantages of ERC include: a) lack of need for donor matching, allowing for “off the shelf” use; b) ability to be injected intravenously; and c) economical production in large scale.

“Dr. Riordan has pioneered the development of practical stem cell based products for treatments of debilitating conditions ranging from Multiple Sclerosis, to Duchenne Muscular Dystrophy, to Heart Failure. The intellectual property portfolio for these products, which are the basis of Medistem’s US-based developmental efforts, provide a deep pipeline of therapeutic candidates,” said Dr. Bogin.

“In contrast to companies who perform research for the sake of research, Medistem’s technologies are actually benefitting patients today, unfortunately only outside of the US. I was attracted to Medistem’s desire to make these treatments available to patients through the tried and tested FDA regulatory route,” said Mr. Zaharchook.

“The fact that Medistem’s ERC cells can be shipped to any facility in the US and administered without need for complex cell processing or injection procedures makes this stem cell product very attractive from a commercialization perspective,” said Dr. Sablin.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

SOMERSET, NJ–(Marketwire – December 6, 2010) – TeamStaff, Inc. (NASDAQ: TSTF), a leading logistics and healthcare services provider to the Federal Government and Department of Defense announced today that its President and Chief Executive Officer, Mr. Zach Parker, will deliver a presentation to investors at the Third Annual LD MICRO Conference on Thursday, December 9, 2010 at 3:00pm PST. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California. A copy of the presentation will be made available in the Investor Relations section of the TeamStaff website (http://teamstaff.com/investor-relations) and also furnished as an exhibit to a Current Report on Form 8-K to be filed by the Company with the SEC.

“I’m pleased to present the TeamStaff story at this year’s LD MICRO investor conference as we believe we have laid the proper foundation to facilitate growth especially into adjacent markets with new customers, like the DoD. I am thankful to participate in this investor conference and I am looking forward to meeting with attendees who specifically have an interest in microcap companies,” said Zach Parker, Chief Executive Officer of TeamStaff.

“We are very pleased to have TeamStaff present at our third annual event,” said Chris Lahiji, President of LD MICRO. “I take pride in having an event that showcases companies of all sizes, in all industries. TeamStaff is a great addition to our roster this year.”

For more information on the conference or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042.

About TeamStaff, Inc.

TeamStaff serves clients and their employees throughout the United States as a full-service provider of logistics and healthcare support services. TeamStaff specializes in providing high quality healthcare, logistics, and technical services to Federal agencies and the Department of Defense. For more information, visit the TeamStaff corporate web site at www.teamstaff.com or the TeamStaff Government Solutions web site at www.teamstaffgs.com.

This press release contains “forward-looking statements” as defined by the federal securities laws and involve numerous risks and uncertainties. TeamStaff’s actual results could differ materially from those described in such forward-looking statements as a result of such risks and uncertainties. For a discussion of such risks and uncertainties, see “Risk Factors” in the Company’s periodic reports filed with the U.S. Securities Exchange Commission. The information in this release should be considered accurate only as of the date of the release. 

DEARBORN, MI–(Marketwire – December 6, 2010) – This year, more than 170,000 Michigan residents receive home-delivered health care from home health care providers, who make over 5 million home visits each year.

Many patients and their families prefer that their loved ones recuperate and/or receive rehab services for surgery, an injury or an acute illness in the comfort and familiar surroundings of their own homes. Trained clinicians, nurses, and therapists are able to provide the same level of attentive, compassionate and personalized in-home care as can be found outside.

Choosing a provider can often be a daunting and frustrating task. To aid the public, Dearborn-based Metro Home Health Care, a leading home health care provider in Michigan, is offering at no cost a Home Health Care Guide that provides basic information for people seeking a home health care agency.

The free booklet may be downloaded from the Metro Home Health Care website, www.metrohomehealthcare.com.

“We think the booklet offers specific things to look for in selecting a home health care agency, and what questions to ask before you make a decision,” said Dr. Agustin V. Arbulu, CEO of Metro Home Health Care. “Our mission has always been to provide best care available to the sick, the elderly or those recovering from surgery in their homes.”

Today’s home care professionals, volunteers, and modern medicine make it possible for people to stay in their homes longer and enjoy an improved quality of life.

Home health care has grown far beyond basic or simple professional nursing and home care aide services. Modern home care agencies like Metro Home Health Care offer a comprehensive scope of services including skilled nursing, physical, occupational, speech therapies, medical social work services, specialty wound care nursing, dietary education, and personal care.

“Metro Home Health Care always has the goal of independence in mind when caring for our neighbors,” said Arbulu.

Home care services are paid for by public and private sources, or directly by patients and their families. Medicare and state-run Medicaid are significant payers and often pay 100 percent of home health services for patients who qualify for such services. Third-party payers include commercial insurance, managed care organizations, and workers’ compensation. Despite deep cuts in government funding, home care continues to be the preferred means of receiving quality health care services for millions of Americans.

With offices in five cities covering 10 counties, Metro Home Health Care provides comprehensive in-home and supportive services for the entire Michigan lower peninsula to acute and chronically ill patients and their families. For more information, please call 313-336-6303 or 800-462-5632, or visit www.metrohomehealthcare.com.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – December 6, 2010) – Physicians in three out of four medical groups of Resurrection Health Care Preferred (RHCP) have earned 11 blue stars — a perfect score — in the 2010 Blue Star Report. The report is a ranking of HMO contracting medical group physicians that have documented high levels of performance in providing patient care from Blue Cross Blue Shield of Illinois (BCBSIL). The Resurrection Health Care Preferred groups earning 11 stars are: Saint Joseph Health Preferred, Saint Mary and Elizabeth Health Preferred and Saint Francis Health Preferred. One group, Resurrection Health Preferred, earned 9 out of 11 stars.

Of the 96 Chicagoland medical groups surveyed, only eight received all 11 blue stars, three of which were part of Resurrection Health Care Preferred. All of the Resurrection Health Care Preferred medical groups received the Blue Ribbon designation — awarded for high patient satisfaction. All of the patients who had RHCP doctors rated their overall satisfaction with their doctor at above 91%.

The medical group’s doctors earn a blue star every time they meet or exceed the target care goal in each of the eleven reporting categories, including asthma care, breast cancer screenings, cardiovascular disease, childhood immunizations, controlling high blood pressure, colorectal screenings, diabetes care, influenza vaccinations, mental health follow-up, cervical cancer screenings and patient safety.

For more information about making Resurrection Health Care Preferred your choice for all your health care needs, call 773-572-8300 and ask for Member Services or visit us at http://www.reshealth.org/findadoctor/why_rhcp.cfm

Resurrection Health Care is the largest Catholic health care system in Chicago with over 100 sites of care. http://www.reshealth.org/

Follow us on Twitter: http://twitter.com/RHC_Outpatient
Visit our YouTube channel: http://www.youtube.com/user/ResurrectionHealth
Join us on Facebook: http://www.facebook.com/pages/Resurrection-Health Care/73879323438?ref=ts  

Click here to see all recent news from this company

THOUSAND OAKS, CA and POTTSTOWN, PA–(Marketwire – December 6, 2010) –  Amgen Inc. (NASDAQ: AMGN) http://www.amgen.com awarded IT&E International http://www.iteinternational.com/ top honors as Veteran-Owned Small Business Contract Staff Supplier in its Supplier Diversity Program.

According to Audrey Porter, IT&E International Vice President, “A special flag-raising ceremony at Amgen’s Thousand Oaks, California headquarters hosted by the Supplier Diversity program was attended by Rocky Chavez, California Secretary of Veteran Affairs, Debbie Gregory Co-Chair of the Veteran and Military Business Owners Association, Ryan Funderburg of IT& E International, and senior Amgen leadership.

“We are extremely grateful to Amgen for this recognition,” continued Ms. Porter, “and appreciate the opportunities to help the company make significant strides in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses,” she said.

About Amgen’s Supplier Diversity Program

Amgen has established a Supplier Diversity Program to ensure that small businesses are not excluded from participating in the supply of goods and/or services required by Amgen. Amgen is committed to identifying and awarding contracts to small, disadvantaged, women-owned businesses consistent with Amgen’s requirements. Amgen strives to identify, develop, and utilize small, disadvantaged, veteran, disabled veteran, and women-owned business enterprises, as well as Historically Underutilized Business Zones (HUBZone), in our procurement program. Amgen’s intent is to support economic development efforts to the extent that jobs may be provided, entrepreneurship may be advanced, and useful goods and/or services may be procured at competitive prices.

About IT&E International

IT&E International offers global regulatory compliance and validation services throughout the product development lifecycle. Consulting services include regulatory planning, providing skilled personnel for development operations, data management to ensure FDA compliance, and validation of new pharmaceutical manufacturing facilities. IT&E International provides our qualified, technical employees to work at pharmaceutical, biotech and life sciences organizations site under client supervision in FDA regulated areas. The company is headquartered at 1610 Medical Drive, Suite 210Pottstown, PA 19464; tel: (610) 340-2012; fax: (610) 340-2007; www.iteinternational.com

TUSTIN, CA–(Marketwire – December 6, 2010) – In its 12 year history, cardiovascular, dermatology and metabolic CRO Integrium has developed and managed over 150 successful clinical trials for clients, consistently beating patient enrollment goals and reducing costs. Integrium provides a therapeutic focus based on deep experience in cardiovascular, dermatological and metabolic trials of all sizes in regions around the world. On the basis of this experience the company offers a full range of services that combine innovative cutting-edge science and technology with practical clinical operations and involve working hands-on with clients, investigators and vendors to deliver high quality service with a sense of immediacy.

Integrium’s smaller size enables it to be far more nimble, and develop a personal rapport and trust with its clients in a way that “mega CROs” simply cannot. 2011 will mark the beginning of Integrium’s 13th year in this highly competitive market, a year the company will usher in with a large cadre of return clients and a team of passionate employees whose dedication is underscored by some of the lowest employee turnover in the business. Its exceptional performance recently caught the attention of the prestigious British pharmaceutical industry journal Scrip Clinical Research, which included Integrium in a cover story on specialty CROs, citing the launch of its dermatological practice as an example of a niche strategy worth watching.

Key Integrium Milestones/Metrics

• 12-year anniversary
  • Founded in 1998 by clinical research thought leaders Dr. David H.G. Smith, MD and Dr. Joel M. Neutel, MD. Dr. Smith and Dr. Neutel continue to lead the company today.
  • Established formal alliances with regional partner CROs in Europe, Australia and India, with numerous additional Integrium locations in North America and South Africa
• 150 successful clinical trials for clients
  • Tightened patient enrollment timelines dramatically and reduced study spend for clients such as Graceway Pharmaceuticals and Resverlogix
  • Consistently differentiated itself by demonstrating a deep understanding of the complexities and nuances of clinical research in its three core focus therapeutic areas: cardiovascular disease, metabolic disease and dermatology
  • Underscoring its success in these trials, 63% of Integrium’s business is with clients for whom it has managed clinical trials before
• Added Dermatology Clinical Research Group in June 2010
  • Helps Integrium clients design scientifically rigorous yet feasible dermatology studies, leveraging its relationships with reliable, high-quality investigators to help identify and recruit study patients, and effectively manage their studies from start to finish
  • Led by noted dermatology drug development expert Dr. Mary Spellman
• In a business where qualified, motivated professionals are critical to success and turnover is high, Integrium has some of the lowest turnover in the industry, with over 90% of the team remaining intact

Commentary
Dr. David Smith, MD, Founding Partner and Chief Medical Officer, Integrium: “Patient recruitment, enrollment and retention continue to represent a critical bottleneck in clinical research and drug development. We are proud of the results we’ve achieved with clients like Graceway and Resverlogix to ensure that they have the patient subjects they need to get the highest-quality data to run better, safer trials.”

Eileen McAuley, RN, BS, MPA, Chief Operating Officer, Integrium: “We take our mission statement seriously, focusing on integrity as a core value. This translates into our dedication to personalized service from the start of a client’s clinical trial to its completion, rigorous scientific protocols, and unyieldingly high research standards. We are not striving to be the biggest CRO — just the best.”

Dr. Sharon Levy, MD, Senior Vice President of Product Development, Graceway Pharmaceuticals: “Integrium’s keen understanding of our specific therapy areas allows us to stay focused on our primary trial objectives. For a multi-center Phase 2 trial they helped us enroll and randomize many more patients than we thought possible — and did so with a very small drop-out rate and 19 weeks ahead of schedule.”

Dr. Allan Gordon, MD, Ph.D, Senior Vice President, Clinical Development, Resverlogix: “Integrium understands that trial efficiencies come from the ground up. The services team understood that we required a ‘true’ partnership and that success would come from understanding our needs and the complexities inherent in running a 40-site study — and their results exceeded our expectations. That they reduced our cycle so dramatically — by nearly six months — allowed us to come in under budget and see the site results we hoped for.”

Resources

• Press release announcing successful trials with Graceway Pharmaceuticals and Resverlogix
• Press release announcing launch of Dermatology Clinical Research Group
• Overview of Integrium’s expertise as a cardiovascular, dermatology and metabolic CRO
• Follow Integrium on LinkedIn

About Integrium, LLC
Integrium is a therapeutically-focused, full-service contract research organization that specializes in dermatology, cardiovascular and metabolic clinical research. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit http://www.integrium.com.